Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland
Hematologia · 2022
DOI: 10.5603/hcp.a2022.0007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematologia, 2022. Verfasst von Krzysztof Giannopoulos und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Plasma cell myeloma (PCM) is a hematologic malignancy that derives from mature B cells. The prognosis of patients with PCM is highly dependent on the presence of cytogenetic aberrations. Determination of cytogenetic risk enables informing patients about their prognosis and allows for individual choice of therapy. In Poland, cytogenetic risk assessment is a fully reimbursed procedure, and it is recommended to perform such an examination in every diagnosed patient. Therapy of patients with high cytogenetic risk should be planned with consideration of tandem autotransplantation of hematopoietic cells in eligible patients. In patients with refractory or relapsed PCM, treatment with ixazomib in combination with lenalidomide and dexamethasone appears to remove cytogenetic risk.
Zitieren
APA
Giannopoulos, K., Jamroziak, K., Wróbel, T., & Dytfeld, D. (2022). Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland. Hematologia. https://doi.org/10.5603/hcp.a2022.0007
Vancouver
Giannopoulos K, Jamroziak K, Wróbel T, Dytfeld D. Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland. Hematologia. 2022. doi:10.5603/hcp.a2022.0007
BibTeX
@article{Giannopoulos2022,
author = {Giannopoulos, Krzysztof and Jamroziak, Krzysztof and Wróbel, Tomasz and Dytfeld, Dominik},
title = {Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland},
journal = {Hematologia},
year = {2022},
doi = {10.5603/hcp.a2022.0007}
}
EUVIMED